EP
MLTX icon

Eversept Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Eversept Partners’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-71,596
Closed -$3.15M – 75
2024
Q2 		$3.15M Buy
+71,596
New +$3.03M 0.22% 54

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Eversept Partners's MLTX Position: Q3 2024 in Review

Eversept Partners sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2024, closing a stake of 71,596 shares — an estimated $3.15M sold.

Eversept Partners first reported a position in MLTX in Q2 2024 and held it in 1 quarter. The position peaked at $3.15M in Q2 2024. 109 funds tracked by Wall St. Rank hold MLTX as of Q3 2024.

  • Eversept Partners reported no remaining MoonLake Immunotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Eversept Partners sold 71,596 MoonLake Immunotherapeutics shares in Q3 2024, an estimated $3.15M.
  • Eversept Partners first reported a position in MoonLake Immunotherapeutics in Q2 2024 and held it in 1 quarter.
  • Eversept Partners's MoonLake Immunotherapeutics position peaked at $3.15M in Q2 2024.
  • 109 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2024.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.